Search results for "bladder Cancer"
showing 10 items of 211 documents
CORRELATION BETWEEN FIBRONECTIN GENE EXPRESSION AND LOCAL TOXICITY INDUCED BY ADJUVANT INTRAVESICAL THERAPY
2015
THE IMPACT OF RE-TUR ON CLINICAL OUTCOMES IN A LARGE COHORT OF T1G3 PATIENTS TREATED WITH BCG.
2014
Scopo del lavoro Re-TUR is strongly advocated for T1G3, because of the high incidence residual disease and mainly the risk of substaging. Its real clinical value remains to be determined and the clinical factors that may influence the decision. Some authors suggest that when muscle is present in the specimen, re-TUR may be avoided. To evaluate if the presence of muscle or not at the first TUR in T1G3 bladder cancer makes a difference in recurrence, progression and cancer specific survival after re-TUR. Materiali e metodi In a large retrospective cohort of 2530 primary T1G3 initially treated with BCG, 953 (37.7%) had a re-TUR. According to the presence or not of muscle in the specimen of pri…
Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma
2008
OBJECTIVE: To assess the value of nuclear matrix protein-22 (NMP22), compared with urinary cytology, in predicting the recurrence of bladder cancer that is not transitional cell carcinoma (non-TCC). PATIENTS AND METHODS: We tested the sensitivity, specificity and the predictive accuracy of NMP22 in the context of non-TCC bladder cancer recurrence, and compared it to the performance of urinary cytology. The study group comprised 2687 patients with history of non-muscle-invasive bladder cancer from 10 centres across four continents. RESULTS: The mean patient age was 64.8 years and 75.4% were men; of all patients, 513 (19.1%) had positive urinary cytology, 906 (33.7%) had a positive NMP22 test…
Expression of Heat Shock Protein in bladder cancers.
2005
Expression of Heat Shock Protein in bladder cancers.
A prospective observational study on oral administration of Ellagic Acid and Annona Muricata in patients affected by non-muscle invasive bladder canc…
2021
Introduction: BCG and MMC shortage and Covid-19 pandemic, more recently, limit accessibility to maintenance regimen in intravesical prophylaxis against recurrence of non-muscle invasive bladder cancer (NMIBC). Ellagic acid (EA) and Annona muricata (AM) exert antitumor activity against different human tumours. An observational prospective study on the prophylactic effect of oral administration of EA+AM in patients avoiding maintenance regimen is presented. Materials and methods: Patients affected by NMIBC and not undergoing maintenance after a 6-week course of intravesical prophylaxis with MMC or BCG were entered. Tis and very high-risk tumours were excluded. After informed consent, the pati…
PREDICTING BLADDER CANCER AT THE EMERGENCY UNIT: THE IMPACT OF HEMOGLOBIN VALUE
2014
Aim of the study Haematuria represents the most common symptom at presentation in patients with bladder Cancer (BCa). However, no study has tested the predictors of BCa in patients presenting with haematuria. This prospective study was aimed to assess the factors associated with the presence of BCa in patients presenting at our emergency unit due to gross-hematuria. Materials and methods All patients presenting at the emergency unit of our institution for their first episode of gross haematuria between January and December 2012 were evaluated. All clinical patient characteristics, including the ongoing antiplatelets and/or oral anticoagulative treatment, were recorded. Demographical, hemato…
Optimizing intravesical chemotherapy in patients with non muscle invasive bladder carcinoma.
2008
Re: Urinary pH is Highly Associated With Tumor Recurrence During Intravesical Mitomycin C Therapy for Nonmuscle Invasive Bladder Tumor
2011
The authors should be congratulated for their attention to basic and open questions on intravesical therapy of nonmuscle invasive bladder cancer. Intravesical delivery of chemotherapy remains partly empirical, and the pharmacokinetics poorly understood. Every attempt to optimize intravesical therapy should be welcomed. Expensive new strategies to deliver an effective therapeutic tumor dose are currently being explored.1,2 It is reasonable (and mandatory) first to consider and study the basic principles of pharmacokinetics. In this retrospective study Maeda et al investigate the role of pH on the efficacy of intravesical mitomycin C (MMC) in vivo. Their experience shows that urinary pH highe…
Adjuvant intravesical therapy in intermediate risk non-muscle invasive bladder cancer (NMIBC) recurring after first cycle of intravesical treatment.
2011
Introduction and objectives The therapeutic management of intermediate risk NMI-BC recurring after intravesical therapy (IT) is not established. Cystectomy will be offered to patients at higher risk of progression but the majority will be retreated by IT. Although some Authors suggest BCG when intravesical chemotherapy (ICH) fails, some patients are retreated by ICH and some others repeat BCG adopted as first-line treatment. Not many studies have been published on this issue. The response to retreatment by intravesical therapy in terms of recurrence-free rate (RFR) and recurrence-free survival (RFS) is analyzed in 179 intermediate-risk patients. Materials and methods Only intermediate-risk …
Mutant HRAS as novel target for MEK and mTOR inhibitors.
2015
HRAS is a frequently mutated oncogene in cancer. However, mutant HRAS as drug target has not been investigated so far. Here, we show that mutant HRAS hyperactivates the RAS and the mTOR pathway in various cancer cell lines including lung, bladder and esophageal cancer. HRAS mutation sensitized toward growth inhibition by the MEK inhibitors AZD6244, MEK162 and PD0325901. Further, we found that MEK inhibitors induce apoptosis in mutant HRAS cell lines but not in cell lines lacking RAS mutations. In addition, knockdown of HRAS by siRNA blocked cell growth in mutant HRAS cell lines. Inhibition of the PI3K pathway alone or in combination with MEK inhibitors did not alter signaling nor had an imp…